Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat colon cancer? trial launches for MSS patients.

NCT ID NCT07235293

Disease control Sponsor: Kahr Bio Australia Pty Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 4 times

Summary

This study tests if a new combination of drugs (DSP107 and atezolizumab) works better than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). About 90 adults who have already tried other therapies will be randomly assigned to one of the two treatments. Researchers will track how long patients live and how safe the treatments are.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Are ≥ 18 years of age with a life expectancy of \> 3 months. 2. Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy). 3. Measurable disease per RECIST v1.1. Exclusion Criteria: 1. Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids. 2. Unresolved AEs of Grade 2 or higher from prior anticancer therapy. 3. Past or current history of autoimmune disease or immune deficiency. 4. History of other malignancy within 3 years of first study treatment cycle. 5. Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory). 6. Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product. 7. Clinically significant abnormal laboratory safety tests.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Austin Health

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

  • Chris O'brien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Duke University Medical Center - Duke Cancer Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Flinders Medical Centre SA

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

  • Footscray Hospital - Western Health

    RECRUITING

    Footscray, Victoria, 3011, Australia

  • Icon Cancer Centre

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

  • Mayo Clinic

    RECRUITING

    Florida City, Florida, 32224, United States

  • Monash Health

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Port Macquarie Base Hospital (Mid North Coast Cancer Institute), Wrights Road,

    RECRUITING

    Port Macquarie, New South Wales, 2444, Australia

  • Sir Charles Gairdner Hospital

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Sunshine Hospital - Western Health

    RECRUITING

    Saint Albans, Victoria, 3021, Australia

  • The Queen Elizabeth Hospital

    RECRUITING

    Woodville, Adelaide, 5011, Australia

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Texas City, Texas, 77030, United States

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Colorado Cancer Center - Highlands Ranch Hospital

    RECRUITING

    Highlands Ranch, Colorado, 80129, United States

  • University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP)

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Westmead Hospital

    RECRUITING

    Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.